TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Japan Eyes Private Credit as Key Pillar in New Financial Strategy 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Asian Currencies Slip as Dollar Gains Safe-Haven Strength Amid U.S.-Iran Tensions 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
U.S. and Philippines to Build 4,000-Acre Tech Hub Under Pax Silica Initiative 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Morgan Stanley Warns Against Overestimating EV Demand Boost from Rising Oil Prices 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
